Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Phase 2 Interventional

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

NCT02399137
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MM-141, Placebo, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
47
States / cities
Gilbert, Arizona • Anaheim, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

NCT00717457
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
exenatide, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Haleyville, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

NCT04847557
View directory record Official record
Conditions
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Nov 1, 2026, 1:41 PM EST
Terminated Phase 2 Interventional Results available

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Nov 1, 2026, 1:41 PM EST
Recruiting Phase 2 Interventional

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

NCT07825857
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Tirzepatide, Placebo (saline)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Terminated Phase 3 Interventional Results available

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
93
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Nov 1, 2026, 1:41 PM EST
Terminated Phase 3 Interventional Results available

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

NCT00239681
View directory record Official record
Conditions
Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions
Rosuvastatin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years and older
Enrollment
17,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
431
States / cities
Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 2 Interventional Results available

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Uproleselan, Placebo, Melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Nov 1, 2026, 1:41 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

The CARING Study: Creating and Restoring Health Through Nutrition Guidance

NCT05795439
View directory record Official record
Conditions
Type2diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Low-fat, vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

NCT00407030
View directory record Official record
Conditions
Cervical Dystonia
Interventions
incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Nov 1, 2026, 1:41 PM EST
Completed Not applicable Interventional

Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions

NCT04492072
View directory record Official record
Conditions
Cesarean Section, Misoprostol, Oxytocin, High Risk Pregnancy
Interventions
Oxytocin, Misoprostol
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 1, 2026, 1:41 PM EST
Active, not recruiting Phase 2 Interventional

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

NCT05020912
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
ALA, PDT
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 2 Interventional

Effect of PP-01 on Cannabis Withdrawal Syndrome

NCT05494437
View directory record Official record
Conditions
Cannabis Withdrawal
Interventions
PP-01 High Dose, PP-01 Low Dose, Placebo, Nabilone, Gabapentin
Combination Product · Drug
Lead sponsor
PleoPharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Glendale, California • Lemon Grove, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Nov 1, 2026, 1:41 PM EST
Recruiting Phase 3 Interventional

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
27
States / cities
Fresno, California • Glendale, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Recruiting Phase 3 Interventional

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

NCT07382167
View directory record Official record
Conditions
Chronic Idiopathic Constipation (CIC)
Interventions
Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
109
States / cities
Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Gabapentin for Perioperative Pain Relief in Surgical Abortion

NCT04292171
View directory record Official record
Conditions
Pain Control
Interventions
Gabapentin, Placebos
Drug
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 2 Interventional Results available

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Nov 1, 2026, 1:41 PM EST
Recruiting Phase 3 Interventional

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Goodyear, Arizona • Springdale, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of Danicopan in Healthy Adults

NCT05016206
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Nov 1, 2026, 1:41 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Skin Tape Transcriptome Methods in Children

NCT04180644
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin tape strips
Other
Lead sponsor
National Jewish Health
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Nov 1, 2026, 1:41 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT05451771
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Simvastatin's Potential Role in Therapy

NCT00486044
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 69 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

NCT05634811
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Normal Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 17 Years
Enrollment
3,547 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Guntersville, Alabama • Bellflower, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 1, 2026, 1:41 PM EST
Completed Phase 4 Interventional Results available

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

NCT02429258
View directory record Official record
Conditions
Type II Diabetes
Interventions
Farxiga, Placebo, Metformin, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Nov 1, 2026, 1:41 PM EST